Best overall response among patients receiving parsaclisib monotherapy
| Patients . | N . | ORR, n (% [95% CI])* . | CR/CMR, n (%) . | PR/PMR, n (%) . | SD, n (%) . | PD/PMD, n (%) . | Not evaluable/not assessed, n (%) . |
|---|---|---|---|---|---|---|---|
| DLBCL† | 23 | 7 (30 [13-53]) | 4 (17) | 3 (13) | 4 (17) | 11 (48) | 1 (4) |
| GCB | 19 | 6 (32 [13-57]) | 4 (21) | 2 (11) | 3 (16) | 9 (47) | 1 (5) |
| ABC | 2 | 1 (50 [1-99]) | 0 | 1 (50) | 0 | 1 (50) | 0 |
| FL | 14 | 10 (71 [42-92]) | 3 (21) | 7 (50) | 1 (7) | 2 (14) | 1 (7) |
| MZL‡ | 9 | 7 (78 [40-97]) | 3 (33) | 4 (44) | 1 (11) | 1 (11) | 0 |
| MCL§ | 9 | 6 (67 [30-93]) | 4 (44) | 2 (22) | 2 (22) | 0 | 1 (11) |
| HL‖ | 10 | 2 (20 [3-56]) | 0 | 2 (20) | 3 (30) | 4 (40) | 1 (10) |
| CLL§ | 6 | 2 (33 [4-78]) | 0 | 2 (33) | 2 (33) | 1 (17) | 1 (17) |
| WM | 1 | 1 (100 [3-100]) | 0 | 1 (100) | 0 | 0 | 0 |
| Patients . | N . | ORR, n (% [95% CI])* . | CR/CMR, n (%) . | PR/PMR, n (%) . | SD, n (%) . | PD/PMD, n (%) . | Not evaluable/not assessed, n (%) . |
|---|---|---|---|---|---|---|---|
| DLBCL† | 23 | 7 (30 [13-53]) | 4 (17) | 3 (13) | 4 (17) | 11 (48) | 1 (4) |
| GCB | 19 | 6 (32 [13-57]) | 4 (21) | 2 (11) | 3 (16) | 9 (47) | 1 (5) |
| ABC | 2 | 1 (50 [1-99]) | 0 | 1 (50) | 0 | 1 (50) | 0 |
| FL | 14 | 10 (71 [42-92]) | 3 (21) | 7 (50) | 1 (7) | 2 (14) | 1 (7) |
| MZL‡ | 9 | 7 (78 [40-97]) | 3 (33) | 4 (44) | 1 (11) | 1 (11) | 0 |
| MCL§ | 9 | 6 (67 [30-93]) | 4 (44) | 2 (22) | 2 (22) | 0 | 1 (11) |
| HL‖ | 10 | 2 (20 [3-56]) | 0 | 2 (20) | 3 (30) | 4 (40) | 1 (10) |
| CLL§ | 6 | 2 (33 [4-78]) | 0 | 2 (33) | 2 (33) | 1 (17) | 1 (17) |
| WM | 1 | 1 (100 [3-100]) | 0 | 1 (100) | 0 | 0 | 0 |
Assessed by Lugano Classification, International Working Group for CLL Criteria, and the VIth International Workshop on WM by Disease Subtype by CT or PET.
ABC, activated B-cell–like; CMR, complete metabolic response; GCB, germinal center B-cell–like; PD, progressive disease; PMD, progressive metabolic disease; PMR, partial metabolic response; PR, partial response; SD, stable disease.
95% CIs were calculated based on the exact method for binomial distributions.
Two patients had unknown DLBCL subtype.
Includes extranodal MZL of MALT type (n = 2), nodal MZL (n = 4), splenic MZL (n = 2), and unknown MZL subtype (n = 1).
Twelve patients had received ibrutinib before the study, including 4 patients with MCL and 3 patients with CLL, of whom a best overall response of CR or PR was achieved by 2 patients with MCL and 1 patient with CLL.
Includes classic HL (n = 9) and nodular lymphocytic-predominant HL (n = 1).